These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1589 related articles for article (PubMed ID: 8526190)

  • 1. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.
    Feun LG; Robinson WA; Savaraj N; Gonzalez R; Liebmann A; Offenhauser K; Clendeninn NJ
    Am J Clin Oncol; 1995 Dec; 18(6):488-90. PubMed ID: 8526190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
    Feun LG; Gonzalez R; Savaraj N; Hanlon J; Collier M; Robinson WA; Clendeninn NJ
    J Clin Oncol; 1991 Mar; 9(3):464-7. PubMed ID: 1999717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
    Feun LG; Savaraj N; Hurley J; Marini A
    Cancer Invest; 2002; 20(3):357-61. PubMed ID: 12025231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
    Polyzos A; Legha SS; Burgess AM; Benjamin RS; Bodey GP
    Invest New Drugs; 1988 Apr; 6(1):57-61. PubMed ID: 3410667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T
    J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
    Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
    J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
    Yamazaki N; Uhara H; Fukushima S; Uchi H; Shibagaki N; Kiyohara Y; Tsutsumida A; Namikawa K; Okuyama R; Otsuka Y; Tokudome T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):969-75. PubMed ID: 26407818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
    Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
    Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
    Stoter G; Aamdal S; Rodenhuis S; Cleton FJ; Iacobelli S; Franks CR; Oskam R; Shiloni E
    J Clin Oncol; 1991 Sep; 9(9):1687-91. PubMed ID: 1875225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
    Flaherty LE; Robinson W; Redman BG; Gonzalez R; Martino S; Kraut M; Valdivieso M; Rudolph AR
    Cancer; 1993 Jun; 71(11):3520-5. PubMed ID: 8490900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
    Verschraegen CF; Legha SS; Hersh EM; Plager C; Papadopoulos N; Burgess MA
    Eur J Cancer; 1993; 29A(5):708-11. PubMed ID: 8471328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
    Samson MK; Haas CD; Baker LH; Cummings G
    Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.